Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d
The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.
In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.
Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca
More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, acco
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
